AbCellera Biologics (ABCL) Cash from Investing Activities (2020 - 2026)

AbCellera Biologics has reported Cash from Investing Activities for 7 years, with the latest figure at -$25.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 416.08% year-over-year to -$25.1 million; the trailing twelve-month figure through Mar 2026 stood at $54.7 million (down 44.95% YoY), and the FY2025 full-year result was $87.8 million, down 27.72% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$25.1 million, down from $75.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $75.1 million in Q4 2025, with the low at -$282.0 million in Q3 2022.
• Historically, Cash from Investing Activities has averaged -$22.9 million across 5 years, with a median of -$17.1 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 1385.03% — and 2025, when it soared 886.7%.
• AbCellera Biologics' Cash from Investing Activities stood at -$17.1 million in 2022, then slumped by 42.55% to -$24.3 million in 2023, then soared by 246.79% to $35.7 million in 2024, then jumped by 110.45% to $75.1 million in 2025, then tumbled by 133.38% to -$25.1 million in 2026.
• The last three Cash from Investing Activities figures came in at -$25.1 million (Q1 2026), $75.1 million (Q4 2025), and $36.5 million (Q3 2025), per Business Quant data.